Long-term evolving profile of childhood autoimmune blistering diseases: Retrospective study on 38 children.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 15 03 2018
accepted: 03 12 2018
pubmed: 1 2 2019
medline: 3 1 2020
entrez: 1 2 2019
Statut: ppublish

Résumé

Autoimmune bullous dermatoses (AIBDs) in children are uncommon, and their long-term evolution remains unknown. The aim of this retrospective study was to characterize the long-term prognosis of AIBDs that started during childhood. We conducted a monocentric retrospective study, in the French dermatology centre, by including all children affected by AIBDs. The long-term outcome was obtained through a phone call questionnaire. Sixty-three patients were included from January 1993 to December 2015, 34 female and 29 males: 27 Linear immunoglobulin A disease (LAD), 12 bullous pemphigoid (BP), 12 pemphigus, 8 herpetiform dermatitis (DH) and 4 epidermolysis bullosa aquisita (EBA). The mean age was 4.7 years old. Twenty-five patients were lost during the follow-up. For the 38 remaining patients, the mean follow-up duration for all pathologies was 6.6 years. Twenty-nine of them had at least one relapse. Late relapses were observed in two cases of DH and six cases of pemphigus (7-34 months). The mean treatment duration was 30.6 months with variability according to the AIBDs. Topical corticosteroids were used alone, effectively, for seven patients and in association with other treatment in 19 patients in complete remission. Complete remission was noted in 34/38 children with a follow-up of 4.4 years (0.08-19.5). The mean duration to complete remission was 30.5 months (6-114 months). Late nasal synechiae were reported in one EBA only. There was no significant associated comorbidity, but an association with a primary immune deficiency (PID) was observed in two cases. Childhood AIBDs appear to be of good overall prognosis but a long-term follow-up is mandatory, as relapses can be late, except for BP. The use of topical corticosteroids is frequently effective alone or in association. The association with PID leads to think about the possibility of a possible underlying dysimmunity in the child.

Sections du résumé

BACKGROUND BACKGROUND
Autoimmune bullous dermatoses (AIBDs) in children are uncommon, and their long-term evolution remains unknown.
OBJECTIVE OBJECTIVE
The aim of this retrospective study was to characterize the long-term prognosis of AIBDs that started during childhood.
METHODS METHODS
We conducted a monocentric retrospective study, in the French dermatology centre, by including all children affected by AIBDs. The long-term outcome was obtained through a phone call questionnaire.
RESULTS RESULTS
Sixty-three patients were included from January 1993 to December 2015, 34 female and 29 males: 27 Linear immunoglobulin A disease (LAD), 12 bullous pemphigoid (BP), 12 pemphigus, 8 herpetiform dermatitis (DH) and 4 epidermolysis bullosa aquisita (EBA). The mean age was 4.7 years old. Twenty-five patients were lost during the follow-up. For the 38 remaining patients, the mean follow-up duration for all pathologies was 6.6 years. Twenty-nine of them had at least one relapse. Late relapses were observed in two cases of DH and six cases of pemphigus (7-34 months). The mean treatment duration was 30.6 months with variability according to the AIBDs. Topical corticosteroids were used alone, effectively, for seven patients and in association with other treatment in 19 patients in complete remission. Complete remission was noted in 34/38 children with a follow-up of 4.4 years (0.08-19.5). The mean duration to complete remission was 30.5 months (6-114 months). Late nasal synechiae were reported in one EBA only. There was no significant associated comorbidity, but an association with a primary immune deficiency (PID) was observed in two cases.
CONCLUSION CONCLUSIONS
Childhood AIBDs appear to be of good overall prognosis but a long-term follow-up is mandatory, as relapses can be late, except for BP. The use of topical corticosteroids is frequently effective alone or in association. The association with PID leads to think about the possibility of a possible underlying dysimmunity in the child.

Identifiants

pubmed: 30702174
doi: 10.1111/jdv.15456
doi:

Substances chimiques

Dermatologic Agents 0
Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1158-1163

Informations de copyright

© 2019 European Academy of Dermatology and Venereology.

Auteurs

A Welfringer-Morin (A)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

L Bekel (L)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

N Bellon (N)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

A Gantzer (A)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

O Boccara (O)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

S Hadj-Rabia (S)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

S Leclerc-Mercier (S)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.
Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes -Sorbonne Paris Cité, Paris, France.

A Frassati-Biaggi (A)

Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes -Sorbonne Paris Cité, Paris, France.

S Fraitag (S)

Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes -Sorbonne Paris Cité, Paris, France.

C Bodemer (C)

Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne Paris Cité, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH